Please login to the form below
Artios Pharma
This page shows the latest Artios Pharma news and features for those working in and with pharma, biotech and healthcare.
DNA damage specialists Artios Pharma raises $84m
Team behind development of Lynparza focus on next-gen DDR inhibitors. Cambridge, UK-based Artios Pharma has raised $84 million (£65 million) in a series B financing. ... Artios’ existing shareholders Arix Bioscience, SV Health Investors, M Ventures,
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest appointments
-
Artios Pharma appoints science strategy VP
Francis Crick Institute lead Dr Simon Boulton joins management team. Cambridge, UK-based Artios Pharma has appointed Dr Simon Boulton as vice president of science strategy. ... He brings over 20 years of expertise in DNA repair and the treatment of
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
-
Business Director
-
Competitive Salary Offered
-
Account Director, Medical Education
-
Salary TBC
-
Account Manager / Account Director
-
Competative
-
Medical Writer
-
Salary TBC
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
-
Senior Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Senior Account Manager
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- GSK upbeat on its return to oncology market
- BMS and Celgene deal sparks debate on pharma profit motive, more M&A
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- The UK’s new five-year pricing agreement
- Lucid kick-starts 2019 with spellbinding new additions to its writing and account teams
- New hires at Nanoform, Leo Pharma and Calliditas
- Page & Page welcomes Clare Bates to the team
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
BASTARD . LONDON
BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...
Latest intelligence
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- ...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again – in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
